2021, Number 2
Next >>
Rev Cub Med Mil 2021; 50 (2)
Alliances of leading biopharmaceutical companies as a strategic axis for the development of anti-COVID-19 vaccines
Rodríguez PJM, Rodríguez IMM
Language: Spanish
References: 6
Page:
PDF size: 146.71 Kb.
Text Extraction
No abstract.
REFERENCES
ClinicalOmics. NIH to Launch Public-Private Effort to Accelerate Development of COVID-19 Vaccines, Treatments. ClinicalOmics. 2020 [acceso: 27/11/2020]. Disponible en: https://www.clinicalomics.com/topics/patient-care/therapeutics/nih-to-launch-public-private-effort-to-accelerate-development-of-covid-19-vaccines-treatments/
Lambert P, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020 [acceso: 24/11/2020]; 38(31):4783-91. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0264410X2030709X
Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. N Engl J Med. 2020[acceso: 23/11/2020]; 383(10):63. Disponible en: https://www.nejm.org/doi/10.1056/NEJMp2020076
Organización Mundial de la Salud. Prevención y control de infecciones durante la atención médica cuando se sospecha una nueva infección por coronavirus: Guía Provisional. Ginebra: WHO. 2020[acceso: 11/03/2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/330685/9789240001114-
World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO. 2020 [acceso: 23/11/2020]. Disponible en: https://www.whoint/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Ministerio de Salud Pública de Cuba. Plan para la prevención y control del nuevo coronavirus (COVID-19). La Habana: Minsap. 2020. [acceso: 23/11/2020]. Disponible en: https://salud.msp.gob.cu/para-prevenir-y-enfrentar-el-nuevo-coronavirus-la-participacion-popular-es-esencial/
Full text